---
title: "Barley ‘Gluten-Free’ Beers: The Study Questioning Whether Current Controls Are Enough to Protect Celiacs"
description: "A June 2026 study detects immunoreactive barley peptides in gluten-free labeled beers that pass the 20 ppm threshold but can activate celiac disease, questioning the adequacy of current testing methods."
url: https://www.thebeertimes.com/en/barley-gluten-free-beers-immunoreactive-peptides-celiac-disease-study-2026/
date: 2026-06-29
modified: 2026-06-30
author: "Carlos Uhart M."
image: https://www.thebeertimes.com/wp-content/uploads/2018/12/Granos-para-cervezas-sin-gluten.jpg
categories: ["Health"]
tags: ["Health", "Science"]
type: post
lang: en
---

# Barley ‘Gluten-Free’ Beers: The Study Questioning Whether Current Controls Are Enough to Protect Celiacs

A study published in June 2026 detected immunoreactive barley protein fragments in beers marketed as “gluten-free.” The identified peptides comply with the international 20 ppm threshold but retain the capacity to activate celiac disease, calling into question the adequacy of current testing methods.

![Barley ](https://www.thebeertimes.com/wp-content/uploads/2018/12/Granos-para-cervezas-sin-gluten.jpg)*Barley ‘Gluten-Free’ Beers*

The gluten-free beer market has grown steadily over the past decade, driven by rising celiac disease diagnoses and a broader demand for products that non-celiac consumers also perceive as healthier.

A significant share of that supply does not come from alternative cereals—sorghum, rice, or millet—but from barley subjected to enzymatic treatments designed to reduce gluten content below the regulatory threshold.

These are the so-called “gluten-free” or “gluten-reduced” barley beers, and new evidence about their actual safety has just been published that the industry cannot ignore.

## The Problem Is Not Total Gluten: It’s the Peptides

The research, published in June 2026, identified barley protein fragments in beer samples that had passed standard gluten controls. The critical point is not the volume of gluten measured in parts per million, but the nature of what remains after enzymatic treatment: small peptides that escape conventional detection methods yet retain immunogenic activity.

The distinction matters because celiac disease is an autoimmune condition, not an intolerance dependent solely on dose. In individuals with genetic predisposition — carriers of the HLA-DQ2 or HLA-DQ8 alleles — short-chain gliadin or glutenin fragments can trigger the characteristic intestinal inflammatory cascade even when total gluten concentration falls below the threshold considered safe.

The study documents that this scenario is technically possible in beers that have passed the current labeling filter.

## The 20 ppm Threshold and Its Limitations

The international standard—adopted by the Codex Alimentarius and reflected in EU, US and most major market regulations—establishes that a product may be labeled “gluten-free” if it contains less than 20 parts per million of gluten.

The threshold was set on the basis of clinical challenge studies demonstrating that most celiac patients tolerate exposures below that level without detectable short-term intestinal damage.

The problem the 2026 study identifies is methodological: the reference assays—particularly the R5 antibody-based ELISA, the most widely used in the industry—measure total gluten via the reactivity of specific epitopes.

When protein chains have been fragmented by enzymes, some epitopes are no longer detectable by the antibody, but the resulting peptides may still be recognized by the intestinal T lymphocytes of celiac individuals. The 20 ppm threshold measures one thing; the biological activity of the fragments is another matter entirely.

## What Enzymes Do—and What They Don’t

The enzymatic treatment most commonly used in the brewing industry to reduce gluten in barley beers is prolyl endoprotease, commercialized under names such as Brewers Clarex (DSM) or AN-PEP.

These enzymes attack the prolyl bonds in the amino acid sequences of prolamins — specifically gliadins and hordeins in barley — which are precisely the ones that concentrate immunogenic epitopes.

The result is a significant reduction in measurable total gluten content: sufficient, in many cases, to bring levels below 20 ppm. What the study suggests is that enzymatic hydrolysis does not guarantee the elimination of all immunogenic peptides.

Some short fragments derived from barley hordeins may survive the process, maintain the capacity to interact with the intestinal immune system, and go undetected by conventional analytical methods because their structure no longer matches the epitope the reference antibody recognizes.

This is a problem of analytical specificity, not manufacturer bad faith. Enzymatic technology is effective at what it was designed to do: reduce measurable gluten. The study indicates that this may not be sufficient for a subset of highly sensitive celiac consumers.

## Implications for the Craft Beer Sector

Craft beer has a particular relationship with gluten. On one hand, some traditional styles—Berliner Weisse, Gose, and Witbier—use wheat, the most problematic cereal for celiac individuals.

On the other, the craft movement has responded quickly to gluten-free demand, both by brewing with alternative cereals and by adopting enzymatic treatments for their barley and wheat batches.

For breweries producing enzymatically treated barley beers and marketing them as “gluten-free,” the study introduces a communicative responsibility that goes beyond regulatory compliance. C

omplying with the current standard is necessary but, in light of this evidence, may not be sufficient for honest communication with the celiac consumer. The distinction between “meets the 20 ppm limit” and “is safe for every celiac person” has become meaningful.

Some voices in the sector already point toward a dual path: developing more sensitive analytical methods that capture the biological activity of peptides rather than just their total concentration and acknowledging that the only complete guarantee for celiac individuals remains beer brewed from naturally gluten-free raw materials—sorghum, rice, millet, corn, or pseudocereals such as buckwheat or quinoa—without the possibility of cross-contamination.

## Naturally Gluten-Free Alternatives

Brewing beer with naturally gluten-free cereals is not new, but it remains a specialty with a smaller market share than treated barley beers. Sorghum is the most widely used substitute cereal, especially in sub-Saharan Africa, where an ancient tradition of sorghum beers exists. In Western markets, rice, millet, and corn are typically combined with sorghum malts to adjust the flavor profile.

Pseudocereals—buckwheat, quinoa, and amaranth—offer more complex aromatic profiles and are botanically unrelated to the gluten-containing grasses, so they do not present the hordein or gliadin peptide problem.

Their malting is more demanding, and their availability as raw materials for craft brewing is more limited, but the results in styles such as saison, pale ale or amber can be notably good.

The practical conclusion of the study, if confirmed by further research, could accelerate a preference among the most informed celiac consumers toward these alternatives, regardless of what the label on treated barley beers states.

## Frequently Asked Questions

### 1. Are all beers labeled “gluten-free” safe for celiacs?

Not necessarily. There are two distinct categories: beers brewed with naturally gluten-free cereals (sorghum, rice, millet) and barley or wheat beers subjected to enzymatic treatments to reduce gluten below 20 ppm. The June 2026 study suggests the latter may contain immunoreactive peptides that do not raise measurable gluten levels but can still activate celiac disease in sensitive individuals.

### 2. What is an immunoreactive peptide, and why does it matter in beer?

An immunoreactive peptide is a short protein fragment that triggers an inflammatory response in the immune system of a celiac person. In enzymatically treated barley beers, gluten proteins are broken into small peptides that standard ELISA R5 assays may not detect but that can still activate the intestinal T lymphocytes responsible for mucosal damage.

### 3. What does the 20 ppm threshold on gluten-free labeling mean?

It allows a product to be labeled “gluten-free” if it contains less than 20 parts per million of gluten as measured by reference analytical methods (R5 ELISA). The study notes that these methods may not capture short-chain peptides with biological activity that the reference antibody no longer recognizes but the celiac immune system still does.

### 4. What beer is the safest option for a celiac person?

Beer brewed exclusively from naturally gluten-free cereals—sorghum, rice, millet, corn, buckwheat, and quinoa—produced in facilities without cross-contamination with gluten-containing grains. Enzymatically treated barley beers comply with current regulations but may not be suitable for highly sensitive celiac individuals.

## Recommended

- [Auto-Brewery Syndrome: When the Gut Produces Alcohol Without Drinking a Drop](https://www.thebeertimes.com/en/auto-brewery-syndrome-when-the-gut-produces-alcohol-without-drinking/)
- [How to Make Harry Potter Butter Beer? Ingredients and Step-by-Step Guide](https://www.thebeertimes.com/en/how-to-make-harry-potter-butter-beer-ingredients-and-step-by-step-guide/)